Table 1. Assigned Treatment Schedule With Dosage Stratified by Age, Resectability Status at the Time of Diagnosis, and MDACC Classification.
| Variable | No. (%) | Total (N = 570) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at Diagnosis, y | Resectability at Diagnosisa | MDACC Classificationb | |||||||||
| ≤75 (n = 474) | >75 (n = 96) | P Value | Borderline Resectable (n = 233) | Locally Advanced (n = 337) | P Value | A (n = 165) | B (n = 36) | C (n = 32) | P Value | ||
| FOLFIRINOXc | 251 (53.0) | 9 (9.4) | <.001 | 107 (45.9) | 153 (45.4) | .97 | 82 (49.7) | 17 (47.2) | 8 (25.0) | .04 | 260 (45.6) |
| Gemcitabine plus nab-paclitaxeld | 98 (20.7) | 25 (26.0) | <.001 | 56 (24.0) | 67 (19.9) | .28 | 39 (23.6) | 11 (30.6) | 6 (18.8) | .51 | 123 (21.6) |
| GEMOXe | 74 (15.6) | 6 (6.3) | .03 | 24 (10.3) | 56 (16.6) | .04 | 21 (12.7) | 3 (8.3) | 0 | <.001 | 80 (14.0) |
| Gemcitabinef | 51 (10.8) | 56 (58.3) | <.001 | 46 (19.7) | 61 (18.1) | .70 | 23 (13.9) | 5 (13.9) | 18 (56.3) | .09 | 107 (18.8) |
| Complementary radiation therapy | 117 (24.7) | 15 (15.6) | .07 | 49 (21.0) | 83 (24.6) | .37 | 36 (21.8) | 8 (22.2) | 5 (15.6) | .72 | 132 (23.2) |
Abbreviations: FOLFIRINOX, fluorouracil, leucovorin, oxaliplatin, and irinotecan; GEMOX, gemcitabine and oxaliplatin; MDACC, MD Anderson Cancer Center; nab, nanoparticle albumin-bound.
According to National Comprehensive Cancer Network guidelines.
Only for patients with borderline resectable pancreatic ductal adenocarcinoma.
FOLFIRINOX was administered on a 14-day cycle. Fluorouracil was administered as a 400-mg/m2 bolus on day 1, then as a 2400-mg/m2 continuous infusion for 46 hours. Leucovorin calcium, 400 mg/m2; oxaliplatin, 85 mg/m2; and irinotecan hydrochloride, 180 mg/m2, were administered on day 1. Modified FOLFIRINOX was administered without fluorouracil 400-mg/m2 bolus on day 1.
Gemcitabine plus nab-paclitaxel was administered as nab-paclitaxel infusion, 125 mg/m2, followed by a gemcitabine infusion, 1000 mg/m2, on days 1, 8, and 15 every 4 weeks.
GEMOX was administered on a 14-day cycle. Gemcitabine was administered as a 1000-mg/m2 infusion on day 1, followed by an oxaliplatin infusion, 100 mg/m2, on day 2.
Gemcitabine was administered as a 1000-mg/m2 infusion on days 1, 8, and 15 every 4 weeks.